Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
NCT00072033
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
66
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Cancer
Interventions
DRUG:
Cisplatin and Docetaxel
Sponsor
Swiss Cancer Institute